Related Experiment Video
Updated: Jun 22, 2026
05:12
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
Vascular pharmacotherapy and dementia.
1Prince of Wales Medical Research Institute, Randwick NSW 2031, Australia.
Current Vascular Pharmacology
|June 3, 2009
Summary
Vascular disease is linked to dementia and Alzheimer's disease (AD). This review examines how treating cardiovascular risk factors may help prevent or treat dementia.
Area of Science:
- Neurology
- Gerontology
- Cardiovascular Medicine
Background:
- The global population is aging, leading to a significant increase in dementia incidence.
- Growing evidence links vascular disease to cognitive decline and Alzheimer's disease (AD).
- Cardiovascular risk factors like hypertension and diabetes are implicated in dementia development.
Purpose of the Study:
- To review recent advancements connecting vascular disease and dementia, with a focus on AD.
- To evaluate the effectiveness of vascular pharmacotherapy in dementia treatment.
- To explore potential preventative strategies targeting vascular health.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of studies on vascular disease and cognitive impairment.
- Examination of clinical trial data on pharmacotherapy for dementia.
Main Results:
- Vascular factors significantly contribute to cognitive decline and AD.
- Pharmacological interventions targeting cardiovascular risk factors show potential.
- Further research is needed to confirm treatment efficacy.
Conclusions:
- Vascular health is critical for maintaining cognitive function.
- Targeting vascular risk factors may offer a viable strategy for dementia prevention and treatment.
- Pharmacotherapy for vascular conditions warrants further investigation for its role in managing dementia.
More Related Videos
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...